NovaBridge Biosciences reported a net loss of $88.3 million for its fiscal year 2025, a figure that reflects higher research and development spending and one‑time charges linked to the company’s shift toward a U.S.-focused oncology platform. The company’s cash balance stood at $210.8 million as of December 31 2025, giving it a runway that extends through 2028.
The company highlighted progress on its two lead programs. Givastomig, an investigational therapy for gastric cancer, and VIS‑101, a treatment for wet age‑related macular degeneration, both showed positive clinical data, underscoring the potential for future commercialization.
Looking ahead, NovaBridge said it will continue to invest in its pipeline while maintaining a focus on cost discipline. The company’s guidance for 2026 signals ongoing commitment to development and a disciplined approach to spending.
With a substantial cash reserve and a clear focus on its oncology and ophthalmology programs, NovaBridge’s 2025 results illustrate the company’s willingness to absorb short‑term losses in pursuit of long‑term growth. Investors will likely view the continued investment in R&D and the positive clinical milestones as indicators of the company’s strategic trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.